EMA recommends approval of baricitinib for atopic dermatitis
Click Here to Manage Email Alerts
The European Medicines Agency has recommended an extension to baricitinib’s indications to include the treatment of moderate to severe atopic dermatitis, according to a press release.
If approved, Olumiant (baricitinib, Eli Lilly and Company) would be the first JAK inhibitor for the treatment of AD.
“Due to the limited treatment options currently available for adult patients with AD, we’re excited to further explore baricitinib’s potential benefit for patients,” Patrik Jonsson, Lilly senior vice president and president of Lilly Bio-Medicines, said in the release. “At Lilly, we aspire to elevate treatment standards for patients with dermatologic conditions. ... [The Committee for Medicinal Products for Human Use] opinion brings us closer to providing a new medicine for adults living with AD in Europe.”
Olumiant is currently approved in 70 countries for the treatment of rheumatoid arthritis.
Collapse
Press release.
Read more about
Click Here to Manage Email Alerts